MS Drug Pulled from Market Worldwide

MS Drug Pulled from Market Worldwide
MS Drug Pulled from Market Worldwide

A multiple sclerosis (MS) drug is being pulled from the market worldwide after reports of brain inflammation and severe liver damage. Due to safety concerns, Biogen and AbbVie announced that they will be voluntarily withdrawing the drug Zinbryta (daclizumab), an biologic administered once a month to treat relapsing MS. This announcement follows a European Medicines Agency statement indicating that daclizumab would be urgently reviewed because 8 cases of serious inflammatory brain disorders were identified.

When the drug was approved in 2016, the FDA advised that daclizumab should only be used in patients who have failed to respond to 2 or more MS drugs because the treatment may be associated with serious safety risks, including liver damage, immune conditions and life-threatening events.

In a recent statement, Biogen and AbbVie said, “Given the nature and complexity of adverse events being reported, characterizing the evolving benefit/risk profile of Zinbryta will not be possible going forward given the limited number of patients being treated.”

DISCLAIMER: MedShadow provides information and resources related to medications, their effects, and potential side effects. However, it is important to note that we are not a substitute for professional medical advice, diagnosis, or treatment. The content on our site is intended for educational and informational purposes only. Individuals dealing with medical conditions or symptoms should seek guidance from a licensed healthcare professional, such as a physician or pharmacist, who can provide personalized medical advice tailored to their specific circumstances.

While we strive to ensure the accuracy and reliability of the information presented on MedShadow, we cannot guarantee its completeness or suitability for any particular individual's medical needs. Therefore, we strongly encourage users to consult with qualified healthcare professionals regarding any health-related concerns or decisions. By accessing and using MedShadow, you acknowledge and agree that the information provided on the site is not a substitute for professional medical advice and that you should always consult with a qualified healthcare provider for any medical concerns.
Show Comments (0)
0 0 votes
Article Rating
Subscribe
Notify of
guest
0 Comments
Most Voted
Newest Oldest
Inline Feedbacks
View all comments